https://www.thebodypro.com/category/hiv-treatments-in-development/tag/conference-coverage

The Latest

injection

Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions

Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.

By Larry Buhl
Ricardo Diaz

Researcher Behind "Brazil Patient," the Latest HIV Remission Case, Explains How It Happened

The international news story that broke at AIDS 2020, explained by the lead researcher.

By Terri Wilder, M.S.W.
injectable

The Monthly Injectable HIV Drug Works Just as Well When Given Every Two Months

Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.

By Sony Salzman
stem cell transplant device

Durable HIV Remission in London Patient, the Second Person Cured of HIV

Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.

By Sony Salzman
Several Medication Pill Bottles On Table In Front Of Windows

Patients With HIV Should Think About How Many Pills They Take a Day

Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.

By Mathew Rodriguez
Medical: Pills and Syringe

Two-Drug Regimen Is Being Studied as a Long-Acting Injectable. But Does It Work as a Daily Pill?

New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.

By Sony Salzman
Full panel for HIV Treatment Research: New Drugs and More Efficient Regimens press conference

What's New in HIV Treatment: A Report on Updates from IAS 2019

Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.

By Sony Salzman
Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

By Sony Salzman
The Genetic Mutation Behind the Only Apparent Cure for HIV Img

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

By Martha Kempner
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base